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Golgi phosphoprotein 2 (GOLPH2, also termed GP73 and GOLM1) is a type II transmembrane protein residing in the
cis and medial-Golgi cisternae. GOLPH2 is predominantly expressed in the epithelial cells of many human tissues.
Under poorly defined circumstances, GOLPH2 can be cleaved and released to the extracellular space. Despite of its
relatively “young age” since the first description in 2000, the physiological and pathological roles of GOLPH2 have
been the subject that has attracted considerable amount of attention in recent years. Here, we review the history
of GOLPH2’s discovery and the multitude of studies by many groups around the world aimed at understanding its
molecular, cellular, physiological, and pathogenic activities in various settings.
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The 73 kDa protein is coded by the gene GOLM1 located
on human chromosome 9q21.33 (mouse chromosome
13) and was originally cloned by differential screening of
a cDNA library derived from liver tissue of a patient with
adult giant-cell hepatitis [1], a rare form of hepatitis with
suspected viral etiology. GOLPH2 was also independently
identified in “the secreted protein discovery initiative
(SPDI), a large-scale effort to identify novel human
secreted and transmembrane proteins using a biological
signal sequence trap in yeast cells aided by computational
tools [2]. The gene is conserved in chimpanzee, dog,
cow, mouse, chicken, and zebrafish. The closest human
homologue to GOLPH2 is the cancer susceptibility can-
didate gene 4 (CASC4) protein (Swiss-Prot Q6P4E1), a
single-pass type II membrane protein that co-localizes
with GOLPH2 (unpublished data of the authors), the
increased expression level of which is associated with
HER-2/neu proto-oncogene overexpression [3].
GOLPH2 genomic sequence predicts 11 exons and two
splicing variants. The transcript variant 1 (NM_016548.3)
is 3100nt in length and contains exons 2 to 11, while
transcript variant 2 (NM_177937.2) is 3092nt in length* Correspondence: peng_tao@gibh.ac.cn; xim2002@med.cornell.edu
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reproduction in any medium, provided the orand contains exons 1, and 3 to 11. Both variants encode
the same open reading frame. The biological significance
of these variants is not clear.Molecular and biochemical characteristics
of GOLPH2
Sequence analysis reveals that GOLPH2 contains a pre-
dicted transmembrane domain (TMD) at the N-terminal
region, consistent with the observation that the protein
can be found in the serum or cell culture supernatant,
likely by secretion or by a shedding mechanism. Strik-
ingly, it appears that the protein is entirely helical after
the TMD, with two predicted continuous helical regions
of 150 to 200 residues in length (Figure 1A). This strik-
ing helical nature of the protein may explain its observed
resistance to proteases (unpublished data of the authors),
because proteolysis requires a stretch of extended con-
formation such as β-strand conformation or random coil
conformation. The apparent simplicity of the protein
with regards to its secondary structure may also explain
the heat resistance of the protein (unpublished data of
the authors) because the protein may have an extraor-
dinarily high denaturation temperature or may re-fold
readily upon cooling. A search for sequence homology
also revealed that a central region of the protein around
residues 80–190 share low sequence homology (20-30%
identity) to several highly helical proteins, including. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Structural features of GOLPH2. A. Predicted transmembrane (TM) and helical regions of the protein. Approximate residues ranges
are labeled. B. Low but significant sequence homology to proteins with known structures.
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sponse protein (2C2F) (Figure 1B).
The amino acid residues 70–210 may contain a GC-
rich sequence DNA-binding factor-like protein domain
although the significance of this observation is not clear.
Further biochemical and structural characterization of
GOLPH2 will help reveal its oligomerization state, sta-
bility and structural organization of the helices.
To understand how GOLPH2 gene expression is regu-
lated, a 2,599-bp human GOLPH2 promoter fragment
was cloned and characterized in epithelial cells including
Hela, the HCC-derived HepG2, and breast cancer cell
MCF7 [4]. Sequence analysis indicates that GOLPH2
core promoter does not contain the canonical TATA
element. Deletion analyses revealed three important
domains: a repressive region, a positive regulatory region
and a core promoter region. Furthermore, adenoviral
early region 1A (E1A) was able to activate the GOLPH2
promoter, consistent with the original description of
GOLPH2’s induction by viral infection [5]. A GC-box
motif located at −89 to −83 in the core GOLPH2 pro-
moter region partly mediated E1A transactivation [4].
Trafficking of GOLPH2
Under steady-state conditions GOLPH2 is an integral
membrane protein of the cis and medial-Golgi. However,
similarly to the structurally related protein GPP130, it
cycles out of the cis Golgi to endosomes and the cell sur-
face [6]. There is evidence that the endosomal trafficking
of GOLPH2 allows for proprotein convertase furin-mediated cleavage, resulting in its release into the extra-
cellular space, and provides a molecular explanation for
its presence as a serum biomarker for HCC [7]. The
structural determinants for Golgi localization were inves-
tigated using a panel of GOLPH2 truncation mutants [8].
The Golgi localization of GOLPH2 was not affected
by the deletion of the C-terminal part of the protein.
A truncated mutant containing the N-terminal portion
(the cytoplasmic tail and TMD) localized to the Golgi.
Sequential deletion analysis of the N-terminus indicated
that the TMD with a positively charged residue in the cyto-
plasmic N-terminal tail were sufficient to support Golgi
localization. It was also shown that both endogenous and
secreted GOLPH2 exist as a disulfide-bonded dimer, and
the coiled-coil domain was sufficient for dimerization [8].
To note, it has been speculated from the beginning
that GOLPH2 might be important for protein transpor-
tation; however, no direct evidence has been reported
yet demonstrating its role in this process.
GOLPH2 in development
GOLPH2’s physiological importance was inferred by
an early study showing that transgenic mice expressing a
C-terminally truncated GOLPH2 exhibit decreased sur-
vival and hepato-renal pathology with strong inflamma-
tory cell infiltrates [9]. This renal pathology is partially
mimicked in the knockout mice for the lipoprotein clus-
terin (CLU) [10], the secretory form of which (sCLU) has
been shown by us to interact with secretory GOLPH2
through the latter’s C-terminus [11].
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Indeed, studies revealed impressive levels of similarities
between human and Xenopus GOLPH2s. Both proteins
are localized in golgi and forms dimer in a similar man-
ner. More important, both proteins are highly expressed
in epithelial cells, suggesting mechanisms of expression
regulation. In an effort to understand the physiological
function of GOLPH2, the developmental role of
GOLPH2 in the Xenopus model was characterized. Xen-
opus golph2 is expressed in the pronephros during early
development. The morpholino-mediated knockdown of
golph2 results in edema formation. Additionally,
Nephrin expression is enhanced in the glomus, and the
expression of pronephric marker genes, such as atp1b1,
ClC-K, NKCC2, and NBC1, is diminished in the tubules
and duct. The expression of WT1 is increased in the glo-
mus and expanded laterally in the pronephric region,
which may promote glomus formation and inhibit pro-
nephric tubule differentiation [12]. Continued utilization
of a relatively simple but well-defined model system
such as Xenopus laevis will lead to a better understand-
ing of the biological functions, pathogenesis and other
important physiological properties of GOLPH2.GOLPH2 in liver diseases
Clinical studies first uncovered high levels of GOLPH2 in
the sera of patients with liver disease, particularly hepato-
cellular carcinoma (HCC) [13-15]. Compared with α-
fetoprotein (AFP), the most commonly used serum marker
for over four decades, GOLPH2 serum levels appear to be
more sensitive for early HCC [14,16]. Further, GOLPH2 is
hyperfucosylated in HCC, and its hyperfucosylated fraction
in serum is an even better disease marker [13]. The most
profound elevation of serum levels of GOLPH2 has been
detected in patients who have developed HCC on the back-
ground of infections by HCV genotype 1b and HBV [17]. A
recent Chinese study was conducted with systematic review
of related studies, sensitivity, specificity and other measures
about the accuracy of serum GOLPH2 and AFP in the diag-
nosis of HCC using random-effects models. The results of
this study indicate that serum GOLPH2 has a comparable
accuracy to AFP for the diagnosis of HCC, while the value
of serum GOLPH2 in combination with AFP for HCC de-
tection warrants further investigations [18].
In a study aimed to investigate the expression of
GOLPH2 and its correlation with clinical parameters,
significant overexpression of GOLPH2 at either protein-
or mRNA-levels or both were fund to be associated with
aggressive behavior of HCC, but not overall patient sur-
vival [19]. This observation suggests that GOLPH2 is
not merely a marker of HCC progression but it may
have HCC-promoting activities.GOLPH2 in other diseases
GOLPH2 has been described as an excellent ancillary
tissue biomarker for the diagnosis of prostate cancer
[20-22]. One study revealed significantly elevated GOLPH2
expression in lung adenocarcinoma tissues [23]. Interest-
ingly, the levels of soluble GOLPH2 (sGOLPH2) were
about 30% higher in lung cancer patients compared with
healthy individuals [23]. GOLPH2 is consistently overex-
pressed in seminomas compared with matching non-
neoplastic tissues with statistically high significance [24].
GOLPH2 is also highly expressed in the intertubular
Leydig cells as well as in Leydig cell tumors [24]. High
GOLPH2 expression has been observed in normal renal
tubules and in almost half of renal cell carcinomas (RCC)
with a statistically significant predominance in the papil-
lary and chromophobe histological subtypes [25].
A case–control Genome-wide association study
(GWAS) with replication in Canada and the United
Kingdom shows that unadjusted, single nucleotide poly-
morphism (SNP) rs4420638 within APOC1 is strongly
associated with Alzheimer’s disease (AD) due entirely to
linkage disequilibrium with APOE. By multivariable
adjusted analyses, 3 SNPs within the top 120 by P value
in the logistic analysis and 1 in the Cox analysis
of the Canadian data set provides additional evidence
for association at P<0.05 within the United Kingdom
Medical Research Council data set: rs7019241 (GOLPH2),
rs10868366 (GOLPH2), rs9886784 (chromosome 9), and
rs10519262 (intergenic between ATP8B4 and SLC27A2)
[26]. In a study of the Han Chinese population,
rs10868366 and rs7019241 in GOLPH2 were found to be
in strong linkage disequilibrium. Furthermore, the
rs10868366 T/rs7019241 T alleles form a relative protect-
ive factor whereas the rs10868366 G/rs7019241 C alleles
constitute a relative risk factor [27]. Another Chinese
study found that the ApoEE4-associated risk of AD
increased approximately two-fold if the GOLPH2-T allele
of rs7019241 was also present, suggesting that GOLPH2
modifies the ApoEE4-associated risk of AD [28].
GOLPH2’s potential activities in the
immune system
One of the traditional immunological paradigms is
that B-cell and T-cell interactions are a one-way
phenomenon of T-cell help to induce the terminal differ-
entiation of B cells to produce antibodies [29,30]. How-
ever, recently emerging evidence indicates that B cells
may have strong regulatory effects on T cell-mediated
immune responses [31-33]. The mechanisms are not well
understood. A proteomics-based approach was adopted
to identify protein molecules potentially important for
this much underexplored but important pathway of
immunoregulation (unpublished data of the authors). Ini-
tial screening identified a secreted activity by pathogen-
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and by many types of neoplastic B cells spontaneously.
This novel activity strongly suppresses T cell responses in-
directly by modulating dendritic cell (DC) properties
through a selective inhibition of the production of
Interleukin-12 (IL-12), a heterodimeric cytokine essential
for TH1-mediated immunity against intracellular infection
and malignant growth. By a combination of biochemical
and mass spectrometric analyses, it was further deter-
mined that the major activity of this factor was in fact
GOLPH2. The “co-incidental” convergence of the autono-
mously carried out immunological investigations by us
and clinical studies by others on GOLPH2 strongly hints
at the potential importance of this intriguing molecule.
It is tempting to speculate that the sGOLPH2 by HCC
may have a pathological role, which is to inhibit IL-12
production by DCs, thwarting T cell responses against
malignant development. GOLPH2 may also have immune-
independent activities on HCC growth and/or metastasis
in vivo.
The TH1/TH2 balance is impaired in many disorders,
including infectious and autoimmune diseases and ma-
lignancies. In AIDS, for example, there is strong evi-
dence that as the disease progresses hyperactivation of B
lymphocytes and cytokine dysregulation occur, and the
overproduction of type-2 cytokines (IL-4, IL-13, etc.)
promotes TH2 immune responses associated with a per-
missive environment for the survival and persistence of
the virus, accompanied by impaired production of type-
1 cytokines (IL-12, IFN-γ) and diminished cell mediated
immunity (CMI), which is an indispensable and critical
mechanism to eliminate HIV infected cells and control
the spread of infection [34]. Consistent with these obser-
vations, in vivo treatment with recombinant IL-12 pro-
tects mice from immune abnormalities observed during
murine acquired immunodeficiency syndrome (MAIDS)
[35]. IL-12 also enhanced the cellular immune response
in vivo against human HIV-1 env antigen in a DNA
prime/vaccinia virus boost vaccine regimen [36].
It is therefore further postulated that hyperactive B
cells inhibit IL-12 gene expression in DCs by producing
the extracellular GOLPH2, thereby dampening DC/IL-
12-driven CMI against persistent and chronic intracellu-
lar infections in which B cell activation is dysregulated,
such as in HIV/AIDS.
Conclusions
Given its strong association with a number of important
diseases, GOLPH2 is an intriguing molecule that
deserves fruther exploration. Future efforts towards
understanding its roles and mechanisms in physiological
and pathogenic settings can be direted but not limited to
the following aspects: (1) to delineate its potential role
in mammalian development and cellular differentiation;(2) to further study its role in viral infections of epithe-
lial cells; (3) to differentiate the roles of the intracellular
vs the extracellular GOLPH2; (4) to identify its putative
cellular receptor through which the sGOLPH2 induces
intracellular signaling; (5) to investigate the immuno-
logical and non-immune roles of sGOLPH2 in HCC
growth and metastasis in immunocompetent and xeno-
graphic mouse models of HCC, respectively; (6) to inves-
tigate the molecular mechanism of B cell-mediated
evasion of CMI via inhibition of IL-12 synthesis in DCs
by sGOLPH2.
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